Intravitreal Bevasizumab Versus Intravitreal Triamcinolone in Central Retinal Vein Occlusion (CRVO)

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2010
This randomized clinical trial is conducted to evaluate the effect of three intravitreal injections of bevasizumab versus two intravitreal injections of triamcinolone in acute central retinal vein occlusion. The outcomes are visual acuity and central macular thickness. The follow-up time is 6 months.
Epistemonikos ID: ae268f60a9a06099bc8aaa165b4d4424d5126b85
First added on: May 05, 2024